Introduction

Hormone Replacement Therapy (HRT) is indispensable for managing Addison’s Disease, a rare autoimmune condition where the adrenal glands fail to produce sufficient cortisol and aldosterone. By restoring these essential hormones, HRT dramatically improves quality of life and prevents life-threatening adrenal crises. However, when Addison’s Disease coexists with diabetes—or when glucocorticoid replacement unmasks latent insulin resistance—the interplay between therapy and glucose metabolism becomes complex. Missteps in dosing can lead to dangerous hyperglycemia or severe hypoglycemia. This article provides an in-depth, evidence-based exploration of HRT in Addison’s Disease, its effects on blood sugar control, and practical management strategies for the dual diagnosis.

Understanding Addison’s Disease

Addison’s Disease, or primary adrenal insufficiency, most often results from autoimmune destruction of the adrenal cortex. The loss of cortisol and aldosterone produces a constellation of symptoms: profound fatigue, weight loss, orthostatic hypotension, salt craving, hyperpigmentation (especially in skin folds and gums), and gastrointestinal upset. Without treatment, patients are vulnerable to adrenal crisis—a medical emergency characterized by hypotension, shock, vomiting, and electrolyte disturbances. First described by Thomas Addison in 1855, the condition affects approximately 1 in 100,000 people in developed nations, though underdiagnosis is common due to nonspecific early symptoms.

Diagnosis relies on low morning cortisol (< 3 µg/dL) combined with an inadequate response to cosyntropin stimulation testing. Elevated plasma renin activity and ACTH levels confirm primary adrenal insufficiency. Once identified, lifelong HRT is required, and careful attention must be paid to the metabolic effects of these hormones, especially in the context of diabetes.

Hormone Replacement Therapy: Principles and Practice

The goal of HRT in Addison’s Disease is to replicate the body’s natural circadian rhythm of cortisol secretion while replacing aldosterone. Standard therapy includes a glucocorticoid (hydrocortisone, prednisone, or less commonly dexamethasone) taken in two or three divided doses. Hydrocortisone is preferred by many endocrinologists because its short half-life allows more physiologic dosing. For aldosterone replacement, fludrocortisone is given once daily to regulate sodium and potassium balance.

Dosing must be individualized—factors include age, weight, stress level, and concurrent medications. An essential component of management is patient education about “sick day rules”: doubling or tripling the glucocorticoid dose during febrile illness, injury, or surgery to prevent adrenal crisis. Over-replacement, however, can lead to iatrogenic Cushing’s syndrome and worsen insulin resistance. The National Institute of Diabetes and Digestive and Kidney Diseases provides detailed guidelines for patients and providers.

Types of Glucocorticoid Preparations

Hydrocortisone (cortisol) is the most physiologic option, available in immediate-release tablets (typically 10–20 mg upon waking, 5–10 mg at lunch, and 2.5–5 mg in the early evening). Modified-release formulations, such as once-daily hydrocortisone (Plenadren), aim to better mimic the circadian rhythm and may reduce hyperglycemic excursions in diabetic patients. Prednisone and prednisolone have longer half-lives and are sometimes used for convenience, but they produce a less physiologic profile and can cause more pronounced postprandial hyperglycemia. Dexamethasone, with its very long half-life, is rarely used for baseline therapy because of the high risk of overdosing and metabolic side effects.

Replacing Aldosterone

Fludrocortisone (0.05–0.2 mg daily) restores mineralocorticoid activity. In patients with diabetes, careful monitoring of blood pressure and serum potassium is needed because diabetic nephropathy may alter electrolyte handling. In addition, because fludrocortisone does not have significant glucocorticoid activity, it does not directly affect glucose metabolism—but volume status changes can indirectly influence renal gluconeogenesis and medication clearance.

The Intersection of Addison’s Disease and Diabetes

Addison’s Disease frequently coexists with other autoimmune endocrine disorders, a phenomenon known as autoimmune polyendocrine syndrome type 2 (APS-2). Type 1 diabetes is a common component of APS-2, along with thyroid autoimmunity. Patients with established type 1 diabetes may develop Addison’s insidiously; clues include unexplained decreases in insulin requirements, recurrent unexplained hypoglycemia, and worsening fatigue. Conversely, patients with Addison’s Disease are at increased risk of developing type 1 diabetes (or type 2 diabetes, especially if they carry specific HLA haplotypes or have metabolic risk factors). Long-term glucocorticoid therapy can also unmask or worsen insulin resistance, leading to new-onset hyperglycemia in predisposed individuals. A 2019 review in Nature Reviews Endocrinology noted that the prevalence of diabetes in Addison’s patients ranges from 10–25%, depending on the population and diagnostic criteria.

Pathophysiology of Glucocorticoid-Induced Hyperglycemia

Glucocorticoids impair glucose homeostasis through multiple mechanisms: they stimulate gluconeogenesis in the liver, promote glycogenolysis, reduce peripheral glucose uptake by inhibiting insulin signaling in muscle and adipose tissue, and may directly impair pancreatic beta-cell function by inducing oxidative stress. This results in a syndrome of “steroid-induced diabetes” characterized by pronounced postprandial hyperglycemia, especially after the glucocorticoid dose. In patients with pre-existing type 1 or type 2 diabetes, even physiologic replacement doses can disrupt glycemic control. The effect is dose-dependent: higher glucocorticoid doses produce more significant insulin resistance. Interestingly, prednisone and dexamethasone cause more sustained hyperglycemia than divided-dose hydrocortisone, due to their longer half-lives and less physiologic profiles.

Autoimmune Polyendocrine Syndrome and Shared Genetics

The link between Addison’s and diabetes is rooted in shared genetic susceptibility, particularly within the HLA region on chromosome 6. APS-2 typically presents in adulthood with two or more endocrine autoimmune disorders—most commonly type 1 diabetes, Addison’s, and autoimmune thyroid disease. Patients with one of these conditions should be screened for the others if symptoms suggestive of adrenal insufficiency arise. Additionally, non-endocrine autoimmune conditions (such as vitiligo, pernicious anemia, and celiac disease) may coexist, adding further complexity to management.

Clinical Management Strategies for Diabetes in Addison’s Disease

Managing diabetes in a patient with Addison’s Disease requires a coordinated, multidisciplinary approach. The treating endocrinologist should work closely with a diabetes specialist or primary care provider to adjust insulin regimens and monitor glucose trends. The following evidence-based strategies are recommended:

  • Frequent glucose monitoring: Patients should check blood glucose levels at least four times daily, with additional checks around glucocorticoid dosing times. Continuous glucose monitoring (CGM) systems are particularly valuable for capturing post-dosing glucose excursions and nocturnal hypoglycemia. Many CGM platforms now allow remote sharing with care teams, which is especially helpful during illness or dose adjustments.
  • Insulin adjustment in type 1 diabetes: Basal insulin may need to be increased, especially in patients using split-dose hydrocortisone. Mealtime (bolus) insulin often requires upward titration to counter postprandial hyperglycemia after the morning and midday glucocorticoid doses. Conversely, when the glucocorticoid dose is reduced (e.g., during illness recovery or after surgery), insulin doses should be lowered proactively to avoid hypoglycemia. Some patients benefit from a dual-basal approach with separate doses for the glucocorticoid-dominant and non-dominant periods of the day.
  • Oral agents in type 2 diabetes: Metformin is generally safe. Sulfonylureas or meglitinides may need dose adjustment to reduce hypoglycemia risk. SGLT2 inhibitors can be used with caution due to the risk of volume depletion and hypotension—already a concern in Addison’s—and the potential for ketosis. GLP-1 receptor agonists may offer beneficial effects on weight and insulin sensitivity without increasing hypoglycemia risk.
  • Avoiding hypoglycemia: This is a major priority because cortisol deficiency itself can reduce hepatic glucose output. Patients must be educated to distinguish symptoms of hypoglycemia from adrenal insufficiency (both can cause confusion, weakness, and sweating). Sick-day protocols must include both increased glucocorticoid doses and careful glucose monitoring. A low threshold for contacting the healthcare team is essential.

Role of Technology and Self-Management

Insulin pumps with integrated CGM can automate many adjustments and reduce the burden of frequent monitoring. In patients with both conditions, using an automated insulin delivery (AID) system may improve time-in-range while lowering hypoglycemia risk. However, users must be educated that stress-dose glucocorticoids can override the pump’s automated corrections, requiring temporary manual increases in basal and bolus settings. Smartphone apps that track both glucocorticoid dosing and glucose levels can help identify patterns and facilitate communication with the care team.

Special Considerations

Adrenal Crisis in the Diabetic Patient

Adrenal crisis presents a diagnostic and therapeutic challenge in someone with diabetes. Hypoglycemia from excessive insulin or insufficient glucocorticoid can mimic many features of adrenal crisis: altered mental status, hypotension, and weakness. Point-of-care glucose testing is mandatory to differentiate the two. In a true adrenal crisis, prompt administration of injectable hydrocortisone (100 mg intramuscularly) is lifesaving. Emergency kits should be available to all patients, and family members must be trained in injection technique. The presence of diabetes does not change the administration of stress-dose steroids; rather, glucose levels must be monitored closely, and intravenous dextrose given if hypoglycemia persists. After stabilization, insulin doses should be temporarily reduced to account for the stress-dose steroids and the return of endogenous cortisol production (in partial cases) or the tapering of high-dose glucocorticoids.

Pregnancy and the Postpartum Period

Women with both Addison’s Disease and diabetes who become pregnant require specialized care. Glucocorticoid doses often need to be increased in the third trimester to meet increased metabolic demand, but the degree of dose escalation must be balanced against worsening hyperglycemia. Preexisting diabetic nephropathy, hypertension, and preterm labor risk are compounded. A multidisciplinary team including maternal-fetal medicine, endocrinology, and neonatology is recommended. Glucose targets during pregnancy are stricter (fasting < 95 mg/dL, 1-hour postprandial < 140 mg/dL). Insulin requirements typically rise in the second and third trimesters, yet the added glucocorticoid effects may require further upward adjustment.

Postpartum, glucocorticoid doses are typically reduced back to prepregnancy levels within a week, which can precipitate hypoglycemia if diabetes medications are not simultaneously weaned. Breastfeeding is generally safe, but mothers should be educated about the possible passage of glucocorticoids into breast milk and should monitor infant weight and growth. A postpartum follow-up within 2 weeks is essential to reassess both hormone doses and diabetes management.

Surgery and Stress Dosing

Elective or emergency surgery in patients with Addison’s Disease and diabetes necessitates careful perioperative planning. Standard stress-dose protocols (e.g., 100 mg hydrocortisone every 8 hours on the day of surgery, then rapid taper over 24–48 hours) must be implemented. Preoperatively, the diabetes medication regimen should be adjusted: oral agents are usually held the morning of surgery, and insulin infusions may be required. The stress-dose glucocorticoids will cause significant hyperglycemia, often requiring increased insulin delivery during the perioperative period—sometimes as high as 1–2 units per hour above the patient’s usual basal rate. Postoperative glucose management should be proactive, with hourly checks in the recovery unit and a transition to subcutaneous insulin once the patient is stable and eating. The Endocrine Society’s clinical practice guideline on adrenal insufficiency offers detailed perioperative recommendations for stress dosing.

Impact on Diabetic Complications

There is emerging evidence that chronic glucocorticoid replacement may accelerate microvascular complications in diabetes, particularly retinopathy and nephropathy, due to the direct effects of glucocorticoids on vascular endothelial growth factor and renal hemodynamics. Conversely, optimal control of adrenal insufficiency may reduce overall systemic inflammation and potentially slow the progression of some complications. Regular screening for diabetic retinopathy, nephropathy, and neuropathy should be performed annually, and clinicians should have a low threshold for referral to ophthalmology if glucocorticoid-induced changes in intraocular pressure are suspected.

Patient Education and Shared Decision-Making

Empowering patients is central to successful dual management. Key educational components include:

  • Understanding the interplay: Patients should know why glucocorticoid doses can raise blood sugar and why missing doses can cause hypoglycemia. Visual aids showing the timing of peaks and troughs for both hydrocortisone and insulin can help.
  • Sick-day protocols: Written instructions for doubling or tripling glucocorticoid doses during illness, along with specific guidance on when to check glucose and when to contact the team. Many centers recommend a 24-hour helpline for urgent advice.
  • Emergency preparedness: Patients should carry an emergency kit containing injectable hydrocortisone, glucagon (if on insulin), and a medical alert bracelet listing both conditions. Family members should be trained in administration of both injections.
  • Lifestyle modifications: Consistent meal timing, balanced carbohydrate intake, and regular exercise can stabilize glucose levels. Because cortisol influences circadian rhythms, patients should aim for consistent sleep-wake schedules to minimize variability.

Emerging Therapies and Future Directions

Research continues to refine hormone replacement and diabetes management for this complex population. Chronotherapy with once-daily modified-release hydrocortisone (Plenadren) may improve glycemic metrics by better mimicking the cortisol circadian rhythm. Continuous subcutaneous hydrocortisone infusion via pump is being explored in select patients, though it remains experimental. On the diabetes side, newer agents with favorable metabolic profiles—such as ultra-long-acting basal insulins and combined GLP-1/GIP receptor agonists—are being studied in glucocorticoid-associated diabetes. Additionally, closed-loop insulin delivery systems that integrate glucocorticoid dosing information could one day automate the delicate balance required for these patients. Clinical trials are ongoing to evaluate these advanced strategies.

Conclusion

Hormone Replacement Therapy is life-saving for Addison’s Disease, but its effects on glucose metabolism demand careful, individualized management—especially for the many patients who also have diabetes. A multidisciplinary approach, meticulous monitoring, and proactive adjustment of both glucocorticoid and diabetes medications lead to better outcomes, fewer hospitalizations, and improved quality of life. With the right knowledge and tools, patients with both conditions can achieve stable hormone balance and excellent glycemic control, allowing them to lead full, active lives. As research continues to refine dosing strategies and integrate novel technologies, the goal remains clear: safe, effective hormone replacement without compromising metabolic health.